Premium
Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease
Author(s) -
Browning Jeffrey L.
Publication year - 2008
Publication title -
immunological reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.839
H-Index - 223
eISSN - 1600-065X
pISSN - 0105-2896
DOI - 10.1111/j.1600-065x.2008.00633.x
Subject(s) - lymphotoxin , lymphotoxin beta receptor , lymphotoxin alpha , immunology , immune system , autoimmune disease , lymphatic system , biology , tumor necrosis factor alpha , antibody , lymph node
Summary: The lymphotoxin (LT) system is part of the tumor necrosis factor family and is required for lymph node development. It has provided a wonderful tool for the dissection of processes critical not only for lymphoid organ development but also the maintenance of the adult immune architecture and the formation of ectopic organized lymphoid tissues in chronically inflamed sites. A soluble lymphotoxin‐β receptor‐immunoglobulin (LTβR‐Ig) fusion protein can block this pathway and is currently being tested in the treatment of autoimmune disease. This review focuses on the immunological consequences of combined LT and LIGHT inhibition with LTβR‐Ig administration as distinct from the developmental biology.